Oxford Bioscience Partners
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Early Stage, Seed, Series A, Series B, Growth, Late Stage, Pre-IPO
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, Singapore, France, Italy, Denmark, Switzerland, Spain, South Korea, Austria, Netherlands, New Zealand, Sweden, Belgium, Norway, Finland
Industries Focus
- Healthcare
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Medical Research
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Immunology
- Genomics
- Proteomics
- Biopharmaceuticals
Investor Details Founded: 1992
Oxford Bioscience Partners is a venture capital firm specializing in early-stage investments within the life sciences sector. Founded in 1992, the firm has committed over $1 billion in capital and has invested in more than 140 companies globally. Their portfolio spans various life sciences domains, including biotechnology, pharmaceuticals, and medical devices. The firm operates from offices in Boston, Massachusetts, Westport, Connecticut, and Malibu, California, positioning itself to support innovative ventures across the United States and internationally. Oxford Bioscience Partners focuses on identifying and nurturing emerging companies that address critical needs in the medical industry, aiming to stimulate the formation of new industry segments. Their investment strategy encompasses a broad range of stages, from seed funding to pre-IPO investments, reflecting a commitment to supporting companies throughout their growth trajectories. The firm's extensive experience and dedicated team have contributed to the successful development and commercialization of numerous life science innovations, underscoring its role as a significant player in the venture capital landscape. Their approach combines equity financing with management support, providing a comprehensive platform for portfolio companies to thrive in the competitive life sciences market.
Requirements
- Innovative life sciences technologies
- Strong management teams
- Scalable business models
- Potential for significant market impact
- Alignment with Oxford Bioscience Partners' strategic focus areas
Contact
[Official Website Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- Alnylam Pharmaceuticals
- Aegerion Pharmaceuticals
- Aileron Therapeutics
- Aptalis Pharma
- ArQule
- AstraZeneca
- Biogen Idec
- Boston Scientific
- Celgene
- Cytokinetics
- Dendreon
- Dyax
- Eisai
- Endo Pharmaceuticals
- Exelixis
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- ImmunoGen
- Ipsen
Mentioned In
-
$24.95
-
$24.95
-
$19.95
-
$49.95
-
$14.95
-
$99.00
Claim this Investor
Are you an official representative of Oxford Bioscience Partners?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim